Home › Trial NCT05654532
Study of AC699 in Patients With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Locally Advanced or Metastatic Breast Cancer
- Trial IDNCT05654532
- StatusActive Not Recruiting
- PhasePhase 1
- Study typeInterventional
- SponsorAccutar Biotechnology Inc
- Enrollment100
- Start date2022-12-29
- ConditionsBreast Cancer
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.